CMR3 Antibody

What is CCR3 and why is it a significant target for monoclonal antibodies?

CCR3 (CC chemokine receptor 3) is a receptor for CC chemokines, including CCL5/RANTES, CCL7/MCP-3, and CCL11/eotaxin. It plays a crucial role in inflammatory responses and is expressed on the surface of multiple cell types including eosinophils, basophils, a subset of Th2 lymphocytes, mast cells, and airway epithelial cells . The significance of CCR3 as a target stems from its involvement in airway hyperresponsiveness in allergic asthma, ocular allergies, and various cancers . Research has demonstrated that blocking the CCR3 axis can significantly suppress airway eosinophilia and mucus overproduction in asthmatic mice, making it an attractive therapeutic target .

Methodologically, researchers targeting CCR3 must consider its structural characteristics, including four extracellular regions: the N-terminal region (amino acids 1-38), extracellular loop 1 (ECL1, aa 96-111), extracellular loop 2 (ECL2, aa 176-207), and extracellular loop 3 (ECL3, aa 269-285) . These structural elements directly influence antibody binding and functionality.

What techniques are commonly used to evaluate antibody binding to CCR3?

The evaluation of antibody binding to CCR3 typically employs multiple complementary techniques:

• Flow cytometry: This is the primary method for assessing binding of antibodies to cell-surface expressed CCR3. Using cells that stably or transiently express CCR3 (such as CHO-K1 cells transfected with CCR3), researchers can quantitatively measure antibody binding .

• ELISA (Enzyme-Linked Immunosorbent Assay): Used to evaluate binding to synthetic peptides corresponding to specific regions of CCR3, particularly for mapping linear epitopes .

• Chimeric protein analysis: By creating chimeric proteins where regions of CCR3 are substituted with corresponding regions from related receptors (such as CCR8), researchers can determine which extracellular domains are involved in antibody recognition .

• Alanine scanning mutagenesis: This technique involves systematically replacing individual amino acids with alanine to identify specific residues critical for antibody binding. For example, studies have shown that residues Ala2, Phe3, Asn4, and Thr5 of mouse CCR3 are important for C₃Mab-3 binding .

These methodologies provide complementary data on antibody specificity, affinity, and the molecular details of antigen recognition.

How do researchers differentiate between antibodies targeting different epitopes of CCR3?

Differentiating between antibodies targeting different epitopes requires a systematic approach combining multiple methods:

• Competition binding assays: By analyzing whether two antibodies can simultaneously bind to CCR3 or compete for binding, researchers can group antibodies into competition groups that likely share overlapping epitopes .

• Domain swapping: Exchanging domains between CCR3 and related receptors helps determine which extracellular regions are involved in antibody recognition. For example, when testing anti-mouse CCR3 antibodies, researchers created chimeric proteins by substituting four extracellular regions of mCCR3 into the corresponding regions of mCCR8 and evaluated antibody binding to these chimeras .

• Alanine scanning analysis: This provides residue-level resolution of epitopes. Each amino acid in the suspected binding region is systematically mutated to alanine, and loss of antibody binding identifies critical contact residues. For instance, studies revealed that C₃Mab-3 requires four specific residues (Ala2, Phe3, Asn4, and Thr5) for binding, while C₃Mab-4 requires only three (Ala2, Phe3, and Thr5) .

• Confirming expression of mutants: Researchers must verify that mutations don't disrupt proper protein expression, which can be accomplished using control antibodies targeting different epitopes. For instance, C₃Mab-7 was used to confirm surface expression of mCCR3 mutants that had lost binding to other antibodies .

This multi-method approach allows precise mapping of epitopes and classification of antibodies based on their binding characteristics.

What methodological approaches are used for epitope mapping of anti-CCR3 monoclonal antibodies?

Epitope mapping of anti-CCR3 monoclonal antibodies involves sophisticated experimental strategies that progress from broad region identification to specific amino acid resolution:

• Extracellular domain substitution analysis: Initially, researchers create chimeric proteins where extracellular domains of CCR3 are replaced with corresponding regions from homologous receptors. For anti-mouse CCR3 (mCCR3) antibodies, researchers systematically substituted each of the four extracellular regions of mCCR3 (N-terminal region, ECL1, ECL2, and ECL3) into mouse CCR8, which has a similar amino acid structure. Flow cytometry analysis revealed that antibodies C₃Mab-3, C₃Mab-4, and J073E5 recognized chimeras containing the N-terminal region (aa 1-38) of mCCR3, but not chimeras with other extracellular loops, indicating epitope localization to the N-terminus .

• Comprehensive alanine scanning mutagenesis: After identifying the broad region containing the epitope, every amino acid in that region (except structurally critical cysteine residues) is individually substituted with alanine. For N-terminal epitopes of mCCR3, researchers constructed thirty-six alanine substitution mutants expressed in CHO-K1 cells. Flow cytometry analysis of these mutants revealed distinct binding patterns:

  • C₃Mab-3 showed no binding to A2G, F3A, N4A, and T5A mutants

  • C₃Mab-4 lost binding to A2G, F3A, and T5A mutants

  • J073E5 failed to bind to A2G and F3A mutants

• Validation with control antibodies: To ensure that loss of binding is due to disruption of the epitope rather than impaired surface expression, researchers use control antibodies targeting non-overlapping epitopes. For instance, C₃Mab-7, which binds to different residues (Phe15 and Glu16), confirmed surface expression of the N-terminal mutants .

The integration of these approaches enables precise epitope definition at the amino acid level, revealing the molecular basis of antibody specificity.

How do structural characteristics of antibody complementarity determining regions (CDRs) affect binding to CCR3?

The complementarity determining regions (CDRs) of antibodies, particularly the heavy chain CDR3 (CDRH3), play crucial roles in determining specificity and affinity for targets like CCR3:

• CDRH3 sequence diversity: CDRH3 regions show substantial diversity in both sequence composition and length, contributing to their ability to recognize specific epitopes. Studies on antibodies against other targets have demonstrated that CDRH3 sequences can be specifically tailored to recognize particular antigenic structures .

• Structural conformations: The three-dimensional structure of CDRH3 loops determines how they interact with target epitopes. Modeling studies have shown that CDRH3 regions with similar sequences can adopt different conformations, affecting their binding properties. Computational methods like ImmuneBuilder can predict these structures and their interactions with antigens .

• Common CDRH3 motifs: Interestingly, some broadly neutralizing antibodies share common motifs in their CDRH3 regions despite recognizing slightly different epitopes. This suggests that certain structural features are particularly effective at binding conserved regions of target proteins .

• Angle of approach: The orientation by which an antibody's CDRs interact with the target epitope significantly impacts binding characteristics. Even antibodies targeting similar regions can show different breadth and potency based on their angle of approach to the target .

• Germline gene contributions: The germline gene segments (V, D, and J) that recombine to form the antibody influence the framework upon which the CDRH3 sits, affecting its presentation to the antigen. Public antibody classes often utilize specific germline genes (like VH3-53) that predispose the CDRH3 to recognize particular epitope structures .

Understanding these structural principles is essential for designing and characterizing antibodies with optimal binding properties to CCR3 or other targets.

What are the functional implications of antibodies binding to different epitopes of CCR3?

The specific epitope targeted by an anti-CCR3 antibody has significant functional consequences:

• Ligand competition: Antibodies that bind to the N-terminal region of CCR3 may directly compete with natural ligands like CCL11/eotaxin, which also binds to this region. Research has demonstrated that CCL11/eotaxin interacts with the N-terminal region of CCR3, suggesting that antibodies targeting this area may have neutralizing activity by blocking ligand binding .

• Receptor activation or inhibition: Depending on the precise epitope, antibodies may have different effects on receptor signaling. Some may act as antagonists by preventing ligand binding or receptor conformational changes, while others might function as partial agonists or allosteric modulators.

• Therapeutic potential: Anti-CCR3 antibodies that effectively block ligand binding show promise in treating conditions like asthma. Studies have shown that such antibodies can significantly suppress airway eosinophilia and mucus overproduction in asthmatic mice, suggesting that targeted blockade of the CCR3 axis may be an effective therapeutic strategy .

• Differential effects on cell types: CCR3 is expressed on multiple cell types, including eosinophils, basophils, and certain T cells. Antibodies targeting different epitopes may differentially affect these various cell populations, potentially allowing for more selective therapeutic applications.

• Cross-reactivity considerations: The conservation of epitopes across species is an important consideration for translational research. Antibodies targeting highly conserved regions may have broader applicability in different experimental models but could also have unintended cross-reactivity.

Researchers must carefully characterize the functional consequences of epitope-specific binding when developing and applying anti-CCR3 antibodies for both research and therapeutic purposes.

How are AI-based approaches being applied to antibody design and epitope mapping?

Artificial intelligence (AI) technologies are revolutionizing antibody research, particularly in the areas of design and epitope mapping:

• De novo antibody generation: AI-based language models like IgLM can generate novel antibody sequences with specific targeting capabilities. For example, researchers have used these models to create 1,000 de novo CDRH3 sequences with substantial diversity in composition and length . These AI-generated sequences typically differ from naturally occurring antibodies while maintaining target specificity.

• Structural prediction and optimization: AI tools like ImmuneBuilder can model the three-dimensional structure of generated antibody sequences, allowing researchers to predict how they might interact with target epitopes. Comparison of these structures with known antibodies enables refinement of candidates before experimental testing .

• Down-selection based on structural similarity: AI-generated candidates can be ranked by their predicted structural similarity to known effective antibodies, allowing researchers to prioritize the most promising candidates for experimental validation. This approach has shown success rates of approximately 15% in generating antigen-specific antibodies .

• Mimicking natural antibody development: AI approaches aim to replicate the outcome of natural antibody generation processes while bypassing their complexity. By providing a germline gene template and a specific structural epitope target, AI can design CDRH3 sequences with specificity for the target antigen .

• Integration with experimental validation: The most effective approaches combine AI prediction with experimental testing. For example, after computational generation and screening, candidate antibodies can be evaluated in binding assays, neutralization tests, and epitope mapping studies to confirm and refine the AI predictions .

As these technologies continue to advance, the efficiency and accuracy of generating target-specific antibodies through AI approaches are expected to increase significantly, potentially expanding beyond CDRH3 design to comprehensive de novo antibody development .

What controls should be included when characterizing novel anti-CCR3 antibodies?

Proper experimental controls are critical for reliable characterization of anti-CCR3 antibodies:

• Expression controls: When testing antibody binding to CCR3 or CCR3 mutants, researchers must verify that the target protein is correctly expressed on the cell surface. This can be accomplished using:

  • Antibodies targeting known, non-overlapping epitopes (such as C₃Mab-7 for confirming expression of N-terminal mutants)

  • Detection of epitope or fusion tags incorporated into the receptor construct

  • Measurement of mRNA expression through qRT-PCR

• Specificity controls: To confirm antibody specificity, researchers should include:

  • Related receptors with high sequence homology (such as CCR1, CCR2, or CCR5)

  • Parental cell lines lacking CCR3 expression

  • Competition assays with known ligands or antibodies

• Functional assay controls: When evaluating the functional effects of anti-CCR3 antibodies:

  • Include positive control agonists (such as CCL11/eotaxin) to confirm receptor functionality

  • Use isotype-matched control antibodies to identify non-specific effects

  • Test a range of antibody concentrations to establish dose-response relationships

• Epitope mapping controls: For accurate epitope identification:

  • Verify surface expression of all mutant constructs

  • Include antibodies with known epitopes as references

  • Use both gain-of-function (adding CCR3 sequences to non-binding receptors) and loss-of-function (mutating CCR3 residues) approaches

• Cross-validation techniques: Whenever possible, confirm findings using multiple independent methods:

  • Combine flow cytometry with surface plasmon resonance or biolayer interferometry

  • Support cellular binding assays with biochemical approaches like Western blotting

  • Complement binding studies with functional assays measuring signaling outcomes

Incorporating these controls ensures that the observed antibody characteristics are specific, reproducible, and biologically relevant.

What methodological approaches can resolve contradictory results in antibody characterization?

When facing contradictory results in antibody characterization, researchers can employ several strategic approaches:

• Comprehensive epitope analysis: When antibodies show unexpected binding patterns, detailed epitope mapping can resolve discrepancies. For example, some anti-CCR3 antibodies (C₃Mab-6 and C₃Mab-7) recognize both synthetic N-terminal peptides and cell-surface CCR3, while others (C₃Mab-3 and C₃Mab-4) primarily recognize conformational epitopes on cell-surface CCR3 . Understanding these differences explains seemingly contradictory ELISA versus flow cytometry results.

• Conformational considerations: Antibodies may recognize different conformational states of the receptor. Investigating whether the receptor adopts different conformations under various experimental conditions (such as in detergent solutions versus native membranes) can explain disparate results.

• Expression system variables: CCR3 expression levels, post-translational modifications, and membrane composition can vary between expression systems. Systematically comparing antibody binding across multiple expression platforms (e.g., CHO cells, HEK293 cells, and native cells expressing CCR3) can identify system-dependent effects.

• Technical variables elimination:

  • Standardize antibody concentration and incubation conditions

  • Ensure consistent receptor expression levels

  • Control for buffer composition, pH, and temperature

  • Validate secondary detection reagents independently

• Independent methodological approaches: When one technique yields contradictory results, employing orthogonal methods can provide clarity:

  • Compare results from flow cytometry, surface plasmon resonance, and immunoprecipitation

  • Complement binding studies with functional assays measuring signaling or cellular responses

  • Use both recombinant protein fragments and cell-expressed full-length receptors

• Allosteric effects analysis: Some antibodies may induce conformational changes that affect binding of other antibodies or ligands. Investigating these allosteric effects through detailed binding kinetics and competition studies can reveal complex binding interactions explaining contradictory results.

By systematically addressing these variables, researchers can reconcile contradictory findings and develop a more comprehensive understanding of antibody-CCR3 interactions.

What new technologies are advancing the development of highly specific anti-CCR3 antibodies?

Several cutting-edge technologies are enhancing the development of highly specific anti-CCR3 antibodies:

• Cell-Based Immunization and Screening (CBIS): This method has been successfully used to develop anti-mouse CCR3 monoclonal antibodies like C₃Mab-3 and C₃Mab-4. CBIS involves immunizing with cells expressing the native conformation of CCR3, followed by screening against the same cellular expression system. This approach is particularly valuable for membrane proteins like CCR3, which may lose critical conformational epitopes when purified .

• AI-driven antibody design: Artificial intelligence approaches are revolutionizing antibody development. Language models trained on antibody sequences can generate novel CDRH3 regions with target specificity. For example, AI systems can produce diverse antibody sequences that, after structural modeling and down-selection, yield candidates with specific binding properties .

• High-resolution structural analysis: Advanced structural biology techniques, including cryo-electron microscopy and X-ray crystallography, enable detailed visualization of antibody-antigen interfaces. These structural insights allow rational optimization of antibody binding properties and epitope targeting.

• Single B-cell technologies: Methods to isolate and sequence antibodies from single B cells of immunized animals or humans enable rapid identification of naturally occurring antibodies with desired specificity profiles. These approaches efficiently capture the diversity of the immune response.

• Antibody engineering platforms: Technologies for modifying antibody properties through directed evolution, yeast or phage display, and rational design allow researchers to optimize binding, stability, and functionality of anti-CCR3 antibodies after initial identification.

• Humanization and optimization algorithms: Computational approaches for antibody humanization and optimization can transform research antibodies into potential therapeutic candidates while maintaining target specificity and minimizing immunogenicity.

These technological advances, particularly when used in combination, are accelerating the development of anti-CCR3 antibodies with unprecedented specificity, affinity, and functional properties.

How can researchers determine if an anti-CCR3 antibody has potential neutralizing activity?

Determining the neutralizing potential of anti-CCR3 antibodies requires systematic functional assessment:

• Epitope location analysis: Antibodies binding to regions involved in ligand interaction are more likely to have neutralizing activity. For CCR3, the N-terminal region (aa 1-38) is known to interact with ligands like CCL11/eotaxin. Antibodies targeting this region, such as C₃Mab-3 and C₃Mab-4, may compete with ligand binding and exhibit neutralizing activity .

• Ligand competition assays: Direct assessment of whether an antibody can block binding of natural ligands (CCL5/RANTES, CCL11/eotaxin) to CCR3. This can be performed using:

  • Flow cytometry with fluorescently labeled ligands

  • Radioligand binding assays

  • ELISA-based competition assays

  • Surface plasmon resonance measuring ligand-receptor interaction in the presence of antibody

• Signaling inhibition assays: Measuring whether the antibody blocks downstream signaling events triggered by CCR3 activation:

  • Calcium flux assays

  • ERK/MAPK phosphorylation detection

  • cAMP level measurements

  • β-arrestin recruitment assays

• Functional cellular assays: Evaluating inhibition of CCR3-dependent cellular responses:

  • Chemotaxis assays with eosinophils or transfected cell lines

  • Cell activation markers (CD11b upregulation, reactive oxygen species production)

  • Degranulation of eosinophils or mast cells

• In vivo models: Testing the antibody's ability to suppress CCR3-dependent pathologies in animal models:

  • Reduction of eosinophil recruitment in allergen challenge models

  • Suppression of airway hyperresponsiveness and mucus production in asthma models

  • Inhibition of tumor growth in cancer models where CCR3 promotes progression

• Structure-function correlation: Comparing the neutralizing activity of antibodies targeting different epitopes can provide insights into which binding sites are most effective for neutralization. This approach has revealed that anti-CCR3 antibodies can significantly suppress airway eosinophilia and mucus overproduction in asthmatic mice, confirming the therapeutic potential of CCR3 blockade .

Through these complementary approaches, researchers can comprehensively evaluate the neutralizing potential of anti-CCR3 antibodies and identify the most promising candidates for further development.

How do anti-CCR3 antibodies compare in specificity and functionality across different species?

Cross-species reactivity and functional conservation are important considerations when selecting anti-CCR3 antibodies for research:

• Sequence homology considerations: While CCR3 is relatively conserved across mammalian species, key differences exist, particularly in the N-terminal region where many antibody epitopes are located. Human and mouse CCR3 share approximately 65-70% amino acid identity, but epitopes may not be conserved.

• Species-specific antibody development: Many commercially available antibodies are specifically developed against either human or mouse CCR3, with limited cross-reactivity. For example, the anti-mouse CCR3 monoclonal antibodies C₃Mab-3 and C₃Mab-4 were specifically developed for mouse CCR3 using the CBIS method .

• Epitope conservation analysis: Detailed epitope mapping can predict cross-reactivity potential. Antibodies targeting highly conserved regions may recognize CCR3 from multiple species, while those targeting variable regions will be species-specific. For instance, antibodies recognizing the N-terminal residues of mouse CCR3 (like Ala2, Phe3, Asn4, and Thr5) may not bind human CCR3 if these residues differ .

• Functional conservation testing: Even when binding occurs across species, functional effects may differ due to subtle variations in receptor signaling or expression patterns. Researchers should validate neutralizing activity separately for each species of interest.

• Application-specific selection:

  • For translational research, antibodies with cross-reactivity between human and model species are valuable

  • For specific mechanistic studies, highly selective species-specific antibodies may be preferred

  • For therapeutic development, species cross-reactivity helps predict potential efficacy and toxicity

Understanding these species differences is crucial for experimental design and interpretation, particularly when translating findings between model systems and human applications.

What are the most effective strategies for validating antibody specificity in complex biological samples?

Validating antibody specificity in complex biological samples requires rigorous multi-method approaches:

• Genetic validation strategies:

  • Testing antibody binding in CCR3 knockout cells or tissues (negative control)

  • Using CCR3 overexpression systems (positive control)

  • Employing siRNA or shRNA knockdown to create graduated levels of target expression

  • CRISPR-Cas9 edited cell lines with specific epitope modifications

• Peptide competition assays: Pre-incubating the antibody with synthetic peptides corresponding to the epitope should block specific binding in biological samples. For example, peptides containing the N-terminal sequence of CCR3 would block antibodies like C₃Mab-3 that recognize this region .

• Multiple antibody concordance: Comparing results using multiple antibodies targeting different epitopes of CCR3. Concordant results with antibodies recognizing distinct epitopes (such as C₃Mab-3 targeting Ala2-Thr5 versus C₃Mab-7 targeting Phe15-Glu16) increase confidence in specificity .

• Orthogonal detection methods:

  • Combining immunodetection with mRNA analysis (qRT-PCR, in situ hybridization)

  • Correlating protein detection with functional assays specific to CCR3

  • Mass spectrometry validation of immunoprecipitated proteins

• Cellular context controls: When analyzing tissue samples:

  • Using cell types known to express CCR3 (eosinophils, certain T cells) as positive controls

  • Including cell types that don't express CCR3 as negative controls

  • Validating staining patterns against known cellular distribution of CCR3

• Heterologous expression systems: In cases of ambiguity, reconstituting the expression of CCR3 in cells naturally lacking the receptor can confirm antibody specificity.

These comprehensive validation approaches ensure that signals detected in complex biological samples genuinely represent CCR3 rather than non-specific binding or cross-reactivity with other chemokine receptors.

How can researchers distinguish between closely related epitopes when characterizing antibody binding to CCR3?

Distinguishing between closely related epitopes requires high-resolution analytical techniques: